An interventional study of BERANI in Topical Corticosteroid Phobia, sponsored by Gadjah Mada University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Gadjah Mada University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to understand the prevalence of topical corticosteroid phobia and to identify if personalized behavior intervention method can reduce the score of topical corticosteroid phobia among parents or caregivers of children with atopic dermatitis. The aims of the study are:
Researchers will compare BERANI method to a standard care to see if BERANI method will reduce the score of topical corticosteroid phobia.
Participants will:
85 studies on the registry are indexed under Phobic Disorders; 16 are open to participants now.
This study's planned enrollment of 90 is above the median of 66 across 70 interventional studies indexed under Phobic Disorders.
Browse Phobic Disorders studies →Gadjah Mada University is the lead sponsor of 64 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for: B (Brief screening); E (Express concerns); R (Reassure \& rectify); A (Audiovisual education); N (Navigate understanding); I (Intensify follow-up)
Behavioral: BERANI
Patient will receive a standard education related to topical corticosteroid use for atopic dermatitis
BERANI is a personalized behavior intervention to manage the topical corticosteroid phobia among parents of children with atopic dermatitis. BERANI stands for: 1. B (Brief screening) Screening using TOPICOP questionnaire to identify the scale of topical corticosteroid phobia 2. E (Express concerns) Parents or caregivers are given chance to express their concern to apply topical corticosteroid 3. R (Reassure \& rectify) Physicians respond emphatically to their concerns and explain the safety and use of corticosteroid 4. A (Audiovisual education) One or more audiovisual educational will be delivered (2-3 minutes), with content tailored to the specific topics of concern 5. N (Navigate understanding) Parents will be asked to reiterate their understanding using the teach-back method and develop a simple plan for implementing the therapy 6. I (Intensify follow-up) WhatsApp-based reinforcement through educational materials, videos, and therapy-use reminders during the 2-week follow-up.
Topical Corticosteroid Phobia Score
The topical corticosteroid phobia score will be assessed using TOPICOP instrument in Bahasa Indonesia.
Time frame: From enrollment to the end of intervention at 2 weeks
Compliance of Topical Corticosteroid Use for Atopic Dermatitis
Compliance of topical corticosteroid use will be assessed using 12-item Medication Adherence Scale (MAS) in Bahasa Indonesia.
Time frame: From enrollment to the end of intervention at 2 weeks
Disease Severity of Atopic Dermatitis
The disease severity of atopic dermatitis will be assessed using EASI score.
Time frame: From enrollment to the end of intervention at 2 weeks
No study locations are listed for this record.
Plan to share: No
Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.
Of 28 interventional studies with no phase under Phobic Disorders, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 44. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gadjah Mada University